What are the safety concerns of levetiracetam and can an overdose be fatal?

Safety Profile of Levetiracetam and Overdose Fatality Risk

Levetiracetam has an excellent safety profile in overdose, with no documented fatal overdoses in the medical literature despite ingestions exceeding 20 times the therapeutic dose, though severe cases can require respiratory support and hemodialysis. 1

Overdose Safety Data

The FDA label provides the most authoritative guidance on overdose management 1:

• Highest documented dose: 6000 mg/day in clinical trials with only drowsiness reported
• Postmarketing overdose symptoms: Somnolence, agitation, aggression, depressed consciousness, respiratory depression, and coma
• No specific antidote exists
• Hemodialysis removes approximately 50% of levetiracetam in 4 hours and should be considered in severe overdoses or patients with renal impairment

Real-World Overdose Evidence

The most compelling safety data comes from a 2011 poison center study of 222 single-agent levetiracetam ingestions 2:

• Zero deaths reported
• Only 1 case (0.5%) resulted in major outcome
• 89.2% had minimal or no effects
• In children ≤6 years, no major outcomes occurred

A 2013 case report documented a patient who ingested over 22,500 mg (358 mg/kg) with no significant sequelae 6.5 hours post-ingestion 3. However, clinical vigilance remains necessary as one patient in the literature became obtunded with significant respiratory distress requiring intubation.

Documented Serious Complications

While fatalities are not documented, serious adverse events can occur:

Cardiovascular toxicity 4:

• Bradycardia and hypotension reported with 60-80 g ingestion
• Potentially responsive to atropine and IV fluids
• Mechanism may involve muscarinic receptor effects at high concentrations

Acute kidney injury 5:

• First documented case requiring hemodialysis in 2022
• Rapidly progressing renal failure can occur
• Dialysis is beneficial and should not be delayed

Postmortem data 6:

• Two suicidal deaths in 2010 with elevated levetiracetam levels (190 and 35 mg/L)
• Drug was noted as contributing to death but not sole cause
• Therapeutic range: 10-40 mcg/mL

Common Adverse Effects at Therapeutic Doses

From clinical trials 7:

• Dizziness, somnolence, asthenia, headache, infection (most frequent)
• Behavioral problems, depression, psychosis (less common)
• Discontinuation rates: 7-13% for adverse events at therapeutic doses
• Higher doses (4000 mg without titration) increase somnolence and asthenia

Hematologic effects 1:

• Minor decreases in WBC and neutrophil counts (statistically significant but clinically minimal)
• Mean decrease of 0.4 × 10⁹/L in WBC
• No patients discontinued for hematologic abnormalities

Critical Management Points

Overdose management 1:

1. Contact Poison Control Center immediately
2. Consider gastric lavage if recent ingestion (maintain airway)
3. Provide supportive care with vital sign monitoring
4. Initiate hemodialysis for:
   • Severe symptoms (respiratory depression, coma)
   • Significant renal impairment
   • Clinical deterioration despite supportive care

Common pitfalls to avoid:

• Underestimating potential for acute kidney injury in overdose
• Delaying hemodialysis when indicated
• Failing to monitor for delayed respiratory depression (can occur hours post-ingestion)

Bottom Line

Levetiracetam overdose is rarely life-threatening, with no clearly documented fatal overdoses as the sole agent. The drug's wide therapeutic index makes it one of the safest antiepileptic medications in overdose situations. However, severe cases can require intensive respiratory support and hemodialysis, particularly when complicated by acute kidney injury or cardiovascular toxicity. The absence of documented fatalities should not lead to complacency—aggressive supportive care and consideration of hemodialysis remain essential in severe overdoses.